Skyvia Launches Public API Beta for Data Workflow Automation
PRAGUE, April 16, 2025 (GLOBE NEWSWIRE) -- Skyvia, the most comprehensive data integration platform, has announced the beta release of its highly anticipated Public API. The new feature responds directly to customer requests for enhanced flexibility, programmatic control, and streamlined automation in managing their data workflows. Designed for IT professionals and business users, the Skyvia Public API beta is now available for testing, offering a robust solution to integrate, manage, and optimize data across 200+ supported cloud applications, databases, and services.
'Businesses expressed a need for greater control over their Skyvia resources, such as integrations, automations, endpoints, and more, along with the ability to integrate Skyvia into their existing tech stacks. The Public API beta delivers on these demands, enabling users to programmatically manage Skyvia resources,' said Oleksandr Khirnyi, Chief Product Officer at Skyvia. 'Skyvia has always been about simplifying and automating complex data processes. With the launch of our API Beta, we're giving teams even more control, enabling them to trigger and manage Skyvia operations through custom scripts and build fully automated, end-to-end data workflows,' he added.
Key Features of Skyvia API Beta:
Resource Management: Programmatically manage accounts, agents, automations, backups, connections, endpoints, integrations, and workspaces.
Secure Authentication: Requires an API token passed via the Authorization header, ensuring safe and controlled access (details available in the API Reference).
Seamless Integration: Connects Skyvia with external systems, enabling custom workflows and real-time data operations.
Beta Access: Free for all users during the beta phase, inviting feedback to refine and enhance the API before its full release.
Get Started with Skyvia API Beta Skyvia API Beta is now available, with additional functionality planned for future updates. To learn more, visit the API Reference or explore the Swagger documentation for an interactive experience.
About Skyvia Skyvia is a no-code cloud data integration platform for ETL, ELT, Reverse ETL, data migration, one-way and bi-directional data sync, workflow automation, real-time connectivity, and more. With a vast library of 200+ connectors, Skyvia provides seamless integration among various cloud applications, databases, and data warehouses, including Salesforce, Dynamics CRM, QuickBooks Online, SQL Server, Amazon Redshift, Google BigQuery, and others.
Key Solutions:
ETL, ELT, and Reverse-ETL
Workflow Automation
SaaS Backup & Restore
Real-Time Connectivity
Online SQL Query Builder
For more information, visit Skyvia's website.
Media Contact: Natalia Polomkina
nataliiap@skyvia.com
skyvia.com
Na zertvach St., 2230/44 suite
Prague
18000, CZ
CZ
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c9c84139-0011-4c1d-a90d-5b9728562993
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
LifeVantage Hosts Activate 2025, Unveils New Quarterly Business Campaign and Incentive to Drive Global Growth
SALT LAKE CITY, July 15, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation® (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, held its global Activate 2025 virtual event on Saturday, July 12. The event, supported by Consultant-hosted watch parties and local in-person gatherings, provided a dynamic platform to inspire Consultant business engagement and growth. Activate 2025 also celebrated innovation, reinforcing LifeVantage's ongoing commitment to evolving the direct selling model in today's fast-paced market. LifeVantage introduced its bold 'Summer in the Fast Lane' campaign during the event, building on the Company's 'Drive' message launched in January to encourage Consultants to tap into their internal motivations and take proactive control of their success. Designed to reward consistent business performance, 'Summer in the Fast Lane' offers multiple ways for Consultants at every rank to qualify for new sales incentives, including exclusive mini trips worldwide, while fostering engagement and reach on social channels. Another component of 'Summer is the Fast Lane' is the new High Speed Health Stack, which features MindBody GLP-1 System™, Protandim® Nrf2 Synergizer®, PhysIQ™ Fat Burn, and for the first time ever – a free Protandim® NAD Synergizer®. Together, the powerful stack offers a synergistic approach to weight management, metabolic activation, and long-term wellness.* 'Summer in the Fast Lane' is the first campaign of a new quarterly business cadence designed to drive business growth. The campaign theme, incentive prizes, and product stacks, will refresh every quarter to encourage growth sprints and continuous momentum. In addition to powerful training sessions and roundtable discussions with top Consultants, Global Activate 2025 also announced the next U.S. Momentum Academy, scheduled for October 23-25 in Dallas, TX. This fast-paced, high-impact event will feature in-person training, dynamic keynotes, and next-level networking opportunities. 'We are excited to introduce 'Summer in the Fast Lane', the first campaign in our new quarterly cadence designed to incentivize global growth,' said Steve Fife, President and CEO of LifeVantage. 'We were inspired by our Consultant's seeing the most business success – their energy, their ideas, and the way they support one another to create a sense of connection that uniquely differentiates our model. With this new quarterly cadence, we will foster business growth through shorter, more focused sales sprints, while also strengthening the community that fuels it. When people feel supported and connected, real growth happens – as evidenced by the excitement surrounding Activate 2025.' For more information on LifeVantage and its activating products, visit About LifeVantage CorporationLifeVantage Corporation (Nasdaq: LFVN), the Activation company, is a pioneer in nutrigenomics—the study of how nutrition and naturally occurring compounds can unlock your genes and the health coded within. Our products work with your unique biology and help your body make what it needs for health. The line of scientifically validated activators includes the flagship Protandim® family of products, TrueScience® Liquid Collagen, the newest MindBody GLP-1 System™, Activation-supporting nutrients such as Omega, D3+, and the Rise AM & Reset PM System®, as well as AXIO® nootropic energy drink mixes, the full TrueScience® line of skin and hair care products, and Petandim®, a pet supplement formulated to combat oxidative stress in dogs. Our independent Consultants sell our products to Customers and share the business opportunity with entrepreneurs seeking to begin their own business. LifeVantage was founded in 2003 and is headquartered in Lehi, Utah. For more information, visit *These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Public Relations Contact: CerconeBrownCompanylifevantage@ Investor Relations Contact: Reed Anderson, ICR (646) 277-1260
Yahoo
22 minutes ago
- Yahoo
OncoC4 to Present at the 2025 Orphan Drug Summit on Strategies to Eliminate Anti-Drug Antibodies in Orphan Therapies
Multipronged approach to overcome the challenge of anti-drug antibodies to serve as the foundation of new subsidiary, AdaMunix ROCKVILLE, Md., July 15, 2025 (GLOBE NEWSWIRE) -- OncoC4, Inc., a late-stage biopharmaceutical company developing novel medicines for cancer, today announced it will present at the upcoming 2025 Orphan Drug Summit being held July 16-27, 2025, in Boston, Massachusetts. The presentation will include information on novel platforms developed to address the challenges of anti-drug antibodies (ADAs), which will serve as the basis for OncoC4's new subsidiary, AdaMunix. 'ADAs are a pervasive barrier to protein-based therapeutics, diminishing drug efficacy and contributing to significant adverse events,' said Yang Liu, PhD, Co-Founder, Chief Executive Officer (CEO), and Chief Scientific Officer (CSO) of OncoC4. 'To overcome these challenges, we've established multiple platforms designed to eliminate ADAs and enhance the efficacy and safety of antibody, enzyme, and gene therapies. Through AdaMunix, we aim to harness the potential of these technologies to make a dramatic impact on the lives of patients across a wide range of indications.' AdaMunix's ADA-X technology is designed to create drug-specific agents that neutralize ADAs when combined with approved therapeutics, and in vivo studies have demonstrated near-complete elimination of ADAs for several approved drugs. Its complementary BCR-X technology enables the development of next-generation ADA-stealth protein therapeutics inherently resistant to ADA activity. Based on promising preclinical results, AdaMunix has advanced three programs to pre-IND development. For more information, visit Presentation Details Title: Platform to Eliminate Anti-Drug Antibodies in Orphan Therapies Date: Thursday, July 17, 2025 Time: 11:00 – 11:25 AM ET Presenter: Yang Liu, PhD, Co-Founder, CEO and CSO About OncoC4 Based in Rockville, Maryland, OncoC4 is a privately held, late-stage biopharmaceutical company that is actively engaged in the discovery and development of novel biologicals for the treatment of cancer and immunological diseases. OncoC4's pipeline features assets with first-in-class and best-in-class potential targeting both novel and well validated targets across oncology and immunological diseases. Among them, AI-081 is a fully owned and potentially best-in-class bispecific antibody candidate targeting PD-1 and VEGF. AI-081 is currently enrolling patients in a Phase1/2 trial that could enable two or more pivotal studies. In addition, OncoC4 has a strategic collaboration with BioNTech to co-develop gotistobart (BNT316/ONC-392), a next-generation anti-CTLA-4 antibody candidate, in multiple solid tumor indications, including an ongoing pivotal clinical trial in squamous non-small cell lung cancer. More information: CONTACTS OncoC4Investor Contact:Bill BegienOncoC4, FoliasLifeSci Advisorsafolias@ Media Contact: Jason Braco, Communicationsjbraco@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
22 minutes ago
- Yahoo
Prestige Consumer Healthcare to Release Fiscal 2026 First Quarter Earnings Results
TARRYTOWN, N.Y., July 15, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2026 first quarter earnings release on Thursday, August 7, 2025 before the opening of the market. The Company will host a conference call to discuss the results that same morning at 8:30 a.m. ET. To participate in the live Internet webcast of the conference call, it can be accessed from the Investor Relations page of To participate in the conference call via phone, participants may register for the call here to receive dial-in details and a unique pin. While not required, it is recommended to join 10 minutes prior to the event start. A conference call replay will be available for approximately one week following completion of the live call and can be accessed on the Company's Investor Relations page. About Prestige Consumer Healthcare Inc. Prestige Consumer Healthcare markets, sells, manufactures and distributes consumer healthcare products to retail outlets throughout the U.S. and Canada, Australia, and in certain other international markets. The Company's diverse portfolio of brands include Monistat® and Summer's Eve® women's health products, BC® and Goody's® pain relievers, Clear Eyes® and TheraTears® eye care products, DenTek® specialty oral care products, Dramamine® motion sickness treatments, Fleet® enemas and glycerin suppositories, Chloraseptic® and Luden's® sore throat treatments and drops, Compound W® wart treatments, Little Remedies® pediatric over-the-counter products, Boudreaux's Butt Paste® diaper rash ointments, Nix® lice treatment, Debrox® earwax remover, Gaviscon® antacid in Canada, and Hydralyte® rehydration products and the Fess® line of nasal and sinus care products in Australia. Visit the Company's website at CONTACT: Investor Relations Contact Phil Terpolilli, CFA, 914-524-6819 irinquiries@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
